Amydis gets $3.4 million from NIH commercialization

Amydis gets $3.4 million from NIH commercialization

SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) — Amydis Inc., a privately held, clinical-stage company pioneering an eye tracker platform to enable imaging of ocular disease biomarkers, today announced that it has received a dual-authorization Commercial Readiness Program (CRP) grant for $3.4 million from the National Institutes of Health. The grant will fund the use of novel fluorescent tracers to develop a comprehensive database of retinal biomarkers that identify the heterogeneity of Alzheimer’s disease pathogenesis.

Alzheimer’s disease, the most common form of dementia, is a mechanistically heterogeneous condition that can involve the accumulation of several molecular biomarkers: amyloid beta, alpha-synuclein, tau and TDP-43. Understanding differences in the manifestations of these biomarkers among Alzheimer’s patients will enable precise treatment, enabling clinicians to provide better patient care.

“Our clinical study using the new retinal tracker is the first step in leveraging the eye as a ‘window to the brain’ to enable the creation of a first-in-class multimodal database of retinal images for affordable, non-invasive retinal imaging.” “Widely accessible diagnostic assessment of the heterogeneity in the Alzheimer’s disease spectrum,” said Dr. Stella Sarraf, AMIDES Founder and CEO. “Treating Alzheimer’s disease as a heterogeneous disorder is likely to improve outcomes in the search for effective treatments.”

Amydis is creating a multi-omics data repository that will combine unique ocular molecular biomarkers with blood biomarkers and genomics to enable AI-powered precision medicine to treat Alzheimer’s and other neurodegenerative diseases.

Amydis is developing a proprietary platform that tracks small molecules that bind to misfolded protein deposits, including amyloid beta, alpha-synuclein, and TDP-43. The company has generated extensive proof-of-concept data from live imaging studies in animal models of Parkinson’s, Alzheimer’s, and other conditions, as well as post-mortem studies using cadaveric retinas from patients with Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS).

“Despite the growing consensus that Alzheimer’s disease is a mechanistically heterogeneous condition, there are no diagnostic methods to distinguish the relative contributions of different pathogenic processes in individual patients. This represents a major impediment to progress in developing new therapies and accurately applying existing therapies in a cascade,” Al-Sarraf added. Alzheimer’s disease. “Our tracer enables the creation of a first-of-its-kind multimodal retinal image database that includes biomarkers in central nervous system tissue that characterize Alzheimer’s disease. This approach is fundamental to developing precision therapies by enhancing scoring and monitoring efficacy against multiple disease-relevant biomarkers.

Research reported in this release was supported by the National Institute on Aging of the National Institutes of Health under Award Number SB1AG050454. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Amydis

Amedis is developing new patented molecules, “optical tracers,” that allow direct visualization of molecular changes associated with central nervous system diseases (biomarkers) in the eye. With this first-of-its-kind capability, AMIDES is poised to revolutionize the ability of doctors and researchers to explore the eye for a wide range of diseases, which until now have required long-term clinical evaluation and the use of invasive tests for definitive diagnosis. . The company has a proprietary discovery platform and technical know-how that makes it the first mover and global leader in the development of eye tracking devices for human diseases. The future of effective and sustainable healthcare depends on the knowledge gained through early diagnosis.

For more information contact: info@amydis.com

(tags for translation) Amydis

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *